OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Uzzo on a Biomarker Analysis of the IMmotion010 Trial in RCC

July 31st 2024

Robert Uzzo, MD, MBA, FACS, discusses a biomarker analysis of the IMmotion010 trial in patients with renal cell carcinoma.

Dr Choudhury on Survival Advantages With AR Pathway Inhibitors in mHSPC

July 31st 2024

Atish D. Choudhury, MD, PhD, discusses the background of the A-DREAM trial in patients with metastatic hormone-sensitive prostate cancer.

Dr Bekaii-Saab on the Future of Treatment For Patients With GI Cancer

July 31st 2024

Tanios Bekaii-Saab, MD, FACP, discusses the future of treatment within the gastrointestinal cancers armamentarium.

Dr Msaouel on Ongoing Research With Bispecific Antibodies in RMC and Epithelioid Sarcoma

July 31st 2024

Dr Dreicer on Managing Biochemical Failure Post-Radical Prostatectomy in Prostate Cancer

July 31st 2024

Robert Dreicer, MD, discusses complexities surrounding biochemical failure post radical prostatectomy in patients with prostate cancer.

Dr Wong on Challenges Incorporating Checkpoint Inhibitors into Curative-Intent Regimens in HNSCC

July 31st 2024

Deborah J. Wong, MD, PhD, discusses challenges incorporating checkpoint inhibitors into curative-intent approaches for patients with head and neck squamous cell carcinoma.

Dr Lynce on the Prognosis of Patients With Inflammatory Breast Cancer

July 30th 2024

Filipa Lynce, MD, discusses the current prognosis of patients diagnosed with inflammatory breast cancer subtypes.

Dr Shields on Incorporating Tarlatamab into Clinical Practice for ES-SCLC

July 30th 2024

Misty D. Shields, MD, PhD, discusses the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.

Dr Riess on Advancements in Thymic Epithelial Malignancy Management

July 30th 2024

Jonathan W. Riess, MD, MS, discusses advancements, as well as unmet needs in the management of thymic malignancies.

Dr Nawfal on Radiological Tumor Burden as an Independent Prognostic Factor of Survival in mccRCC

July 30th 2024

Rashad Nawfal, MD, discusses radiological tumor burden as an independent prognostic factor for survival in metastatic clear cell renal cell carcinoma.

Dr Pollyea on the Mechanism of Revumenib in KMT2A-Rearranged R/R AML

July 30th 2024

Dan Pollyea, MD, MS, discusses the mechanism of action for the menin inhibitor revumenib in KMT2A-rearranged relapsed/refractory acute myeloid leukemia.

Dr Patel on Areas of Advancement in the NSCLC Treatment Landscape

July 30th 2024

Sandip P. Patel, MD, discusses significant areas of advancements in the treatment paradigm for non–small cell lung cancer.

Dr Desai on Unmet Needs With Chemoimmunotherapy in NSCLC

July 30th 2024

akash Desai, MBBS, MPH, discusses unmet needs with the use of chemoimmunotherapy in patients with non–small cell lung cancer.

Dr Neparidze on the Implications of Early Data for Belantamab Mafodotin Plus Elotuzumab in R/R Myeloma

July 30th 2024

Natalia Neparidze, MD, discusses clinical implications and future of belantamab mafodotin and elotuzumab in heavily pretreated, relapsed/refractory multiple myeloma.

Dr Sen on the Goal to Identify Actionable Biomarkers of Interest in SCLC

July 30th 2024

Triparna Sen, PhD, discusses the importance of identifying actionable or targetable biomarkers for the management of small cell lung cancer.

Dr Peters on the Use of Biomarkers to Inform Treatment Decision-Making in NSCLC

July 30th 2024

Solange Peters, MD, PhD, discusses biomarkers that may inform treatment decision-making prior to immunotherapy use in non–small cell lung cancer.

Dr Das on the ALINA Trial in Early-Stage ALK+ Lung Cancer

July 30th 2024

Millie Das, MD, discusses key trials that have advanced treatment for patients who present with non–small cell lung cancer.

Dr Opat on Sonrotoclax With Zanubrutinib in Relapsed/Refractory CLL and SLL

July 29th 2024

Stephen Opat, MBBS, discusses sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr Ravi on the Potential Use of RCB to Inform Neoadjuvant Strategies in High-Risk Prostate Cancer

July 29th 2024

Praful K. Ravi, MB, BChir, MRCP, discusses the use of residual cancer burden to guide intensified neoadjuvant treatment in high-risk prostate cancer.

Dr Dizman on the Impact of CBM588 on the Gut Microbiome in ICI-Treated Patients With RCC

July 29th 2024

Nazli Dizman, MD, discusses the impact of CBM588 on gut microbiome composition in patients with renal cell carcinoma who received immune checkpoint inhibitors in the first line.